NORCROSS, Ga., May 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) will webcast a corporate update at 9:45 A.M. ET on Thursday, May 21, 2015, immediately following the business portion of the Company's Annual Meeting of Stockholders. Additionally, Peter Traber, M.D., president, chief executive officer and chief medical officer will discuss the Company's pipeline of galectin inhibitor compounds and progress in development of treatments for liver fibrosis and cancer.
Following his presentation, Dr. Traber will answer questions from shareholders present at the meeting. Shareholders not attending the meeting may submit questions in advance for Dr. Traber's consideration; questions should be submitted via email to contact@galectintherapeutics.com no later than May 20, 2015.
The presentation will be webcast live over the internet and can be accessed by logging on to the Galectin Therapeutics website at www.galectintherapeutics.com and entering the password Galectin. The presentation may also be heard via teleconference by dialing (888) 887-4214 (within the United States) or (913) 643-0354 (outside the United States). The passcode for participants is 576978. Please log in approximately 10 minutes before the event to ensure a timely connection.
The webcast will also be archived on the Company's website.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.